#### DOCON TECHNOLOGIES PRIVATE LIMITED

CIN No: U72900KA2016PTC126436

4th Floor, Prestige Blue Chip Software Park, Block 1, Hosur Road, Madiwala Range, Dairy Colony, Bengaluru- 560029

Email Id: legaldocon@gmail.com; Tel No. 080 6823 6823.

June 27, 2022

National Stock Exchange of India Limited	BSE Limited
Exchange Plaza, C-1,	Phiroze Jeejeebhoy Towers,
Block G, Bandra Kurla Complex,	Dalal Street, Mumbai- 400001
Bandra (E), Mumbai – 400 051	

Ref: Disclosures pursuant to Regulation 31(1) and Regulation 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and SEBI Circular dated August 7, 2019 bearing no. SEBI/HO/CFD/DCR1/CIR/P/2019/90.

Sub: Creation of Pledge over (a) 3,76,56,092 shares (comprising 71.18% of the total share capital) of Thyrocare Technologies Limited ("TTL") by Docon Technologies Private Limited ("Docon") (b) 1,42, 53,118 shares and 4,33,367 compulsory convertible debentures (comprising 100% of the total share capital) of Docon by API Holdings Limited ("API"); (c) an encumbrance by way of an event of default in case Docon or API ceases to directly or indirectly exercise Control over TTL or Docon respectively; and (d) restriction on change in capital structure of TTL or Docon (to the extent of the shareholding of TTL held by Docon and the shareholding of Docon held by API, respectively).

Dear Sirs,

Docon has provided exclusive security interest by way of creation of pledge over 3,76,56,092 shares (comprising 71.18% of the total share capital) of TTL held by Docon, and API has provided exclusive security interest by way of creation of pledge over 1,42,53,118¹ shares and 4,33,367 compulsory convertible debentures (comprising 100% of the total share capital) of Docon held by API, on June 23, 2022 in favour of Vistra ITCL (India) Limited (acting in its capacity as debenture trustee for debentures issued by API for an aggregate nominal value of INR 2280,00,00,000/-).

On and from June 23, 2022, an encumbrance has also been created by way of: (i) an event of default in case (a) Docon ceases to directly or indirectly exercise Control over TTL; (b) API ceases to directly or indirectly exercise Control over Docon; and (ii) restriction on change in capital structure of TTL or Docon (to the extent of the shareholding of TTL held by Docon and the shareholding of Docon held by API, respectively).

In this regard, please see attached herewith (a) disclosures pursuant to Regulation 31(1) and 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; and (b) disclosure pursuant to SEBI Circular dated August 7, 2019 bearing no. SEBI/HO/CFD/DCR1/CIR/P/2019/90 with respect to disclosure of reasons for encumbrance by the promoter of listed companies.

<sup>&</sup>lt;sup>1</sup> 1 (one) share is held by Mr. Hardik Dedhia jointly with API

### **DOCON TECHNOLOGIES PRIVATE LIMITED**

CIN No: U72900KA2016PTC126436

4<sup>th</sup> Floor, Prestige Blue Chip Software Park, Block 1, Hosur Road, Madiwala Range, Dairy Colony, Bengaluru- 560029

Email Id: legaldocon@gmail.com; Tel No. 080 6823 6823.

Thanking you

Yours faithfully

For Docon Technologies Private Limited

Hardik Dedhia

**Director** 

DIN: 06660799

Enclosed: As stated above.

#### ANNEXURE - I

Format for disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Thyrocare Technologies Limited ("TTL")
Names of the Stock Exchanges where the shares of the target company	BSE Limited and National Stock Exchange of India Limited
are listed	****
Date of reporting	June 27, 2022
Name of the promoter or PAC on whose share's encumbrance has been	Promoter - Docon Technologies Private Limited ("Docon")
created/released/invoked	PAC - API Holdings Limited ("API")
Details of the creation <del>/invocation/release</del> of encumbrance:	June 23, 2022

### Details of the creation/invocation/release of encumbrance:

Name ofthe promoter (s) or PACs with him(**)	Promot thetar	er holdi get con (1)	DOSES - POROUG	hold alre encur	noter ding ady mbere (2)	Details of events pertaining to encur			j to encumbi	ance (3)		Post event holding of encumberedshares {creation [(2)+(3)] / release [(2)-(3)] / invocation[(2)-(3)]]	
	No. of shares	% of total shar e capit al	% w.r.t diluted share capital( *)	No. of shar es	% of total shar e capit al	Type of event (creation / release / invocatio n)	Date of creation/ invocati on release of encumbr ance	Type of encumbrance (pledge/ lien/ non disposal undertaking/oth ers)	No. of shares	% of total share capital	Name of the entity in whose favor shares encumber ed	No. of shares	% oftotal share capital
Promoter - Docon Technologies Private Limited ("Docon")	3,76,56,092	71.18	70.68	Nil	Nil	Creation	June 23, 2022	1. Creation of Pledge and Encumbrance by way of (i) an event of default in case Docon ceases to directly or indirectly exercise Control over	3,76,56,092	71.18 %	Shares are being pledged in favour of Vistra ITCL (India) Limited (as Debenture Trustee for non-convertible debentures of aggregate	3,76,56,092	71.18%

					Thyrocare Technologies Limited; and (ii) restriction on change in capital structure of TTL (to the extent of the shareholding of TTL held by Docon)	(	nominal value of INR 2280,00,00,00 0/- issued by API)		
PAC - API 1,42,53,118 shares and 4,33,367 compulsory convertible debentures 2 (being shares and compulso ry convertibl e debenture s held by API in Docon)	% Nil	ZiI	Creation	June 23, 2022	1. Creation of Pledge; and 2. Encumbrance by way of: (i) an event of default in case API ceases to directly or indirectly exercise of Control <sup>3</sup> over Docon; and (ii) restriction on change in capital structure of TTL or Docon (to the extent of the shareholding of TTL held by Docon and the shareholding of Docon held by API, respectively).		being pledged s in favour of 4	4,33,367 compulsory convertible	100%

<sup>1</sup> "Control" means, with respect to a Person, cumulatively all of the following:

<sup>(</sup>a) the right to appoint majority of the directors in such Person; and

<sup>(</sup>b) the right to control the management or policy decisions of such Person including by virtue of shareholding or management rights or shareholders agreements or voting agreements or in any other manner.

<sup>&</sup>lt;sup>2</sup> 1 (one) share is held by Mr. Hardik Dedhia jointly with API

<sup>&</sup>lt;sup>3</sup> "Control" means, with respect to a Person, cumulatively all of the following:

<sup>(</sup>c) the right to appoint majority of the directors in such Person; and

<sup>(</sup>d) the right to control the management or policy decisions of such Person including by virtue of shareholding or management rights or shareholders agreements or voting agreements or in any other manner.

# For Docon Technologies Private Limited

Hardik Dedhia

Director

DIN: 06660799 Place: Mumbai

Date: June 27, 2022

### Annexure - II

## Format for disclosure of reasons for encumbrance

(In addition to Annexure - I prescribed by way of circular dated August 05, 2015)

Name of listed company	Thyrocare Technologies Limited ("Thyrocare")
Name of the recognised stock exchanges where the shares of	National Stock Exchange of India Limited and BSE Limited
the company are listed	
Name of the promoter(s) / PACs whose shares have been	Promoter - Docon Technologies Private Limited ("Docon")
encumbered	PAC - API Holdings Limited ("API")
Total promoter shareholding in the listed company	Promoter shareholding in Thyrocare
	No. of shares – 3,76,56,092
	% of total share capital – 71.18%
	PAC shareholding in Docon
	No. of shares – 1,42,53,118 <sup>1</sup>
	No. of CCDs – 4,33,367
	% of total share capital – 100%
Encumbered shares as a % of promoter shareholding	100%
Whether encumbered share is 50% or more of promoter	Yes
shareholding	
Whether encumbered share is 20% or more of total share	Yes
capital	

## Details of all the existing events/ agreements pertaining to encumbrance

		Encumbrance 1
		(Date of creation of encumbrance: June 23, 2022)
non-disposal undert	e (pledge, lien, negative lien, aking etc. or any other , condition or arrangement in rance)	<ol> <li>Encumbrance by Docon (being the Promoter)</li> <li>Creation of pledge over shares of Thyrocare held by Docon;</li> <li>Encumbrance by way of an event of default in case Docon ceases to directly or indirectly exercise Control<sup>2</sup> over Thyrocare Technologies Limited; and</li> <li>Encumbrance by way of a restriction on change in capital structure of TTL (to the extent of the shareholding of TTL held by Docon)</li> </ol> Encumbrance by API (being the PAC)
		<ul> <li>4. Creation of pledge over shares and compulsory convertible debentures of Docon held by API;</li> <li>5. Encumbrance by way of an event of default in case API ceases to directly or indirectly</li> </ul>
		exercise of Control over Docon; and  6. Encumbrance by way of a restriction on change in capital structure of TTL or Docon (to the extent of the shareholding of TTL held by Docon and the shareholding of Docon held by API, respectively)
No. and % of shares e	encumbered	By Docon for shares held in Thyrocare ("Thyrocare Shares"):  1. No. of shares: 3,76,56,092  2. % of total share capital: 71.18 %
		By API for shares held in Docon: ("Docon Shares")  1. No. of shares: 1,42,53,118 <sup>3</sup> 2. No. of CCDs – 4,33,367  3. % of total share capital: 100%
Specific details about the encumbrance	Name of the entity in whose favour shares encumbered (X)	Vistra ITCL (India) Limited (as Debenture Trustee for the debentures of an aggregate nominal value of INR 2280,00,00,000/- issued by API)
	Whether the entity X is a scheduled commercial bank, public financial institution, NBFC or housing finance company? If No, provide the nature of the business of the entity.	No. Trust services
	Names of all other entities in the agreement	Listed company and its group companies (if any) – a) Docon Technologies Private Limited, Holding Company; b) AHWSPL India Private Limited, Aycon Graph Connect Private Limited, Akna Medical Private Limited, and Threpsi Solutions Private Limited, Subsidiary companies of Ultimate Holding Company  Other entities (if any) – Vistra ITCL (India) Limited
	Whether the encumbrance is relating to any debt instruments viz. debenture, commercial paper,	YES  If yes,  1. Name of the issuer: API Holdings Limited

 $<sup>^{1}\,\</sup>mathrm{1}$  (one) share is held by Mr. Hardik Dedhia jointly with API

 <sup>2 &</sup>quot;Control" means, with respect to a Person, cumulatively all of the following:
 (a) the right to appoint majority of the directors in such Person; and

the right to control the management or policy decisions of such Person including by virtue of shareholding or management rights or shareholders agreements or voting agreements or in any other manner.

3 1 (one) share is held by Mr. Hardik Dedhia jointly with API Holdings Limited

Security Cover / Asset	certificate of deposit etc.? If yes, provide details about the instrument, including credit rating  Value of shares on the date	<ol> <li>Details of the debt instrument: unlisted, unrated, secured, redeemable, non-convertible debentures of the face value of INR 1,00,000 (Indian Rupees One Lakh only) each, for an aggregate Nominal Value of INR 2280,00,00,000/- (Indian Rupees Two Thousand Two Hundred and Eighty Crores) issued in two tranches at a discount of 3%. ("Debentures")</li> <li>Whether the debt instrument is listed on stock exchanges?: No</li> <li>Credit Rating of the debt instrument: Debentures are unrated</li> <li>ISIN of the instrument: INEODJ207026, INEODJ207034</li> <li>Value of Thyrocare Shares - INR 23,46,72,76,534.40/- (calculated on the basis of closing)</li> </ol>
Cover Cover / Asset	of event / agreement (A)	price of Thyrocare shares on NSE on 23.06.2022, i.e. Rs. 623.20 per share)  2. Value of Docon Shares – INR 14,71,66,779/- (being the face value of equity shares and Compulsorily Convertible Debentures)
	Amount involved (against which shares have been encumbered) (B)	INR 22,80,00,00,000/-
	Ratio of A / B	1. For Thyrocare shares – 1.03 2. For Docon shares – 0.06
End use of money	Borrowed amount to be utilized for what purpose –  (a) Personal use by promoters and PACs  (b)For the benefit of listed company	<ul> <li>a) Firstly, towards repayment of the existing facilities availed by API Holdings Limited in full, and for on lending to Threpsi Solutions Private Limited, Aycon Graph Connect Private Limited and Ascent Wellness and Pharma Solutions Private Limited solely for the purpose of them repaying the existing facilities availed by each one of them in full; and</li> <li>b) Thereafter, for general corporate purposes and other expenses in relation the Debentures to the extent permitted under the applicable laws.</li> </ul>
	amount, purpose of raising	<b>Schedule for utilization of amount</b> – Amounts were proposed to be utilised for the above purpose immediately on drawdown.
	schedule for utilization of amount, repayment schedule etc. Any other reason (please specify)	Repayment Schedule – the final redemption date for tranche 1 denentures is 4 years from the deemed date of allotment and for tranche 2 debentures is 5 years from the deemed date of allotment.

# For Docon Technologies Private Limited

Hardik Dedhia Director DIN: 06660799

Place: Mumbai Date: June 27, 2022